Effect of Moringa Oleifera on Metformin Plasma Level in Type 2 Diabetes Mellitus Patients
Launched by TITILAYO O FAKEYE · Jun 13, 2017
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Background Plant parts of Moringa oleifera Lam. (Moringaceae) is known to lower blood glucose level and as a result, type 2 diabetes mellitus patients (T2DM) sometimes use it as herbal supplements. This study therefore sought to evaluate the effects of coadministration of Moringa oleifera tea on steady state concentration of metformin in ambulatory T2DM patients attending a tertiary health facility in Nigeria.
Method This study used a non-randomized pre-test and post-test design to evaluate the effects of coadministration of Moringa tea and metformin on selected parameters in T2DM patients...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ambulatory type 2 diabetes mellitus patients from 40 years of age who had supplemented their oral hypoglycaemic drugs with Moringa oleifera in the past but had stopped for over one month were recruited into the study.
- Exclusion Criteria:
- • Patients with co-morbidities such as congestive heart failure, liver disease, and those who had undergone recent surgical procedure were excluded from the study. Other types of patient excluded from the study were: patients on insulin or whose oral hypoglycaemic drug therapy does not include metformin, patients who take alcohol, patients who were on cimetidine, furosemide, nifedipine, ciprofloxacin, rifampicin, anti-retroviral therapy or any other medication with known interactions with metformin. Patients who smoked were also excluded.
About Titilayo O Fakeye
Titilayo O. Fakeye is a distinguished clinical trial sponsor renowned for her commitment to advancing medical research and improving patient outcomes. With a robust background in clinical pharmacology and regulatory affairs, she leads initiatives that prioritize the integrity of clinical trials and adherence to ethical standards. Her collaborative approach fosters partnerships with healthcare professionals and research institutions, ensuring that innovative therapies are rigorously tested and brought to market efficiently. Driven by a passion for patient advocacy, Fakeye's work not only contributes to scientific knowledge but also emphasizes the importance of patient-centered care in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Toyin Famurewa, B.Pharm;MSc
Principal Investigator
Obafemi Awolowo University Hospitals Complex, Ile-Ife, Nigeria
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials